EA201490864A1 - Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов - Google Patents

Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов

Info

Publication number
EA201490864A1
EA201490864A1 EA201490864A EA201490864A EA201490864A1 EA 201490864 A1 EA201490864 A1 EA 201490864A1 EA 201490864 A EA201490864 A EA 201490864A EA 201490864 A EA201490864 A EA 201490864A EA 201490864 A1 EA201490864 A1 EA 201490864A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
etylamine
phenylimidazol
sodium channel
channel modulators
Prior art date
Application number
EA201490864A
Other languages
English (en)
Other versions
EA023375B1 (ru
Inventor
Шаранджит Каур Багал
Марк Иан Кемп
Дункан Чарльз Миллер
Йошихиса Мурата
Original Assignee
Пфайзер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490864(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Лимитед filed Critical Пфайзер Лимитед
Publication of EA201490864A1 publication Critical patent/EA201490864A1/ru
Publication of EA023375B1 publication Critical patent/EA023375B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение касается производных имидазола, их применения в медицине, содержащих их композиций, способов их получения и промежуточных соединений, которые используются в таких способах. Особенно изобретение касается новых имидазольных модуляторов Na1.8 формулы (I)или их фармацевтически приемлемой соли, где R, R, R, Rи Rявляется такими как определенно в описании. Na1.8 модуляторы являются перспективными при лечении широкого спектра расстройств, в частности боли.
EA201490864A 2011-10-26 2012-10-15 Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов EA023375B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
EA201490864A1 true EA201490864A1 (ru) 2014-08-29
EA023375B1 EA023375B1 (ru) 2016-05-31

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490864A EA023375B1 (ru) 2011-10-26 2012-10-15 Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов

Country Status (28)

Country Link
US (1) US9079878B2 (ru)
EP (1) EP2771335A2 (ru)
JP (1) JP5946538B2 (ru)
KR (1) KR101586966B1 (ru)
CN (1) CN103906746B (ru)
AP (1) AP2014007579A0 (ru)
AU (1) AU2012328034B2 (ru)
BR (1) BR112014009102A2 (ru)
CA (1) CA2850925C (ru)
CL (1) CL2014000956A1 (ru)
CO (1) CO6940427A2 (ru)
CR (1) CR20140185A (ru)
CU (1) CU20140046A7 (ru)
DO (1) DOP2014000085A (ru)
EA (1) EA023375B1 (ru)
EC (1) ECSP14013324A (ru)
GT (1) GT201400079A (ru)
HK (1) HK1198650A1 (ru)
IL (1) IL232267A (ru)
MD (1) MD20140037A2 (ru)
MX (1) MX337469B (ru)
NI (1) NI201400031A (ru)
PE (1) PE20141682A1 (ru)
SG (1) SG11201401032YA (ru)
TN (1) TN2014000147A1 (ru)
UA (1) UA109220C2 (ru)
WO (1) WO2013061205A2 (ru)
ZA (1) ZA201402281B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2755980T3 (da) * 2011-09-14 2020-01-27 Dow Agrosciences Llc Fremgangsmåder og systemer til dannelse boronsyre og mellemprodukter deraf
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
WO2016065341A1 (en) 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
JP6762308B2 (ja) 2015-02-19 2020-09-30 パーデュー、ファーマ、リミテッド、パートナーシップ 胃排出の減少方法及び組成物
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US11827899B2 (en) 2015-12-30 2023-11-28 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CA3029132A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP2019520079A (ja) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 疼痛関連障害を処置するための物質及び方法
CA3063901A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
IL308954A (en) 2021-06-04 2024-01-01 Vertex Pharma Solid dosage forms and dosage regimens containing (2R, 3S, 4S, 5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2 -carbonyl]amino]pyridine-2-carboxamide
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
AP2353A (en) * 2004-05-07 2012-02-16 Warner Lambert Co 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands.
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
CA2584785A1 (en) 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
AU2006329040C1 (en) * 2005-12-22 2011-12-08 Newron Pharmaceuticals S.P.A. 2 -Phenylethylamino derivatives as calcium and/or sodium channel modulators
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
BRPI0810202A2 (pt) 2007-05-03 2014-10-21 Pfizer Ltd Derivados de piridina
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
BR112014009102A2 (pt) 2017-04-18
DOP2014000085A (es) 2014-08-31
CL2014000956A1 (es) 2014-07-18
MX2014004738A (es) 2014-08-01
US9079878B2 (en) 2015-07-14
AU2012328034A1 (en) 2014-05-15
HK1198650A1 (en) 2015-05-22
EP2771335A2 (en) 2014-09-03
AP2014007579A0 (en) 2014-04-30
CN103906746A (zh) 2014-07-02
SG11201401032YA (en) 2014-07-30
CO6940427A2 (es) 2014-05-09
MX337469B (es) 2016-03-02
UA109220C2 (ru) 2015-07-27
WO2013061205A8 (en) 2014-03-27
NI201400031A (es) 2014-10-01
IL232267A0 (en) 2014-06-30
IL232267A (en) 2016-10-31
EA023375B1 (ru) 2016-05-31
KR101586966B1 (ko) 2016-01-19
CA2850925C (en) 2017-01-10
CU20140046A7 (es) 2014-10-02
WO2013061205A2 (en) 2013-05-02
AU2012328034B2 (en) 2015-04-23
ECSP14013324A (es) 2014-05-31
US20140296313A1 (en) 2014-10-02
GT201400079A (es) 2015-06-02
JP5946538B2 (ja) 2016-07-06
CR20140185A (es) 2014-06-03
MD20140037A2 (ru) 2014-08-31
NZ623090A (en) 2015-10-30
KR20140069234A (ko) 2014-06-09
WO2013061205A3 (en) 2013-06-27
JP2014530900A (ja) 2014-11-20
ZA201402281B (en) 2015-11-25
PE20141682A1 (es) 2014-11-14
CA2850925A1 (en) 2013-05-02
CN103906746B (zh) 2015-12-09
TN2014000147A1 (fr) 2015-09-30

Similar Documents

Publication Publication Date Title
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX359882B (es) Amidas como moduladores de canales de sodio.
EA201690752A1 (ru) Ингибиторы g12c kras
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201391106A1 (ru) Новые гетероциклические производные
EA201390381A1 (ru) Триазиноксадиазолы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201591195A1 (ru) Новые хинолоновые производные
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201600434A1 (ru) Применение производных бензимидазолпролина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU